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Apoptosis is a physiological mechanism of cell death
that plays an important role in the regulation of tissue
homeostasis. The regulation of apoptosis is a complex
process and involves a number of gene products includ-
ing the survival factor Bcl-2, which has been found to be
frequently deregulated in human cancers. In addition to
deregulation of apoptosis, the process of neoplasia is
also believed to be driven by the activation of telomer-
ase, a ribonucleoprotein complex that adds telomeric
repeats (hexanucleotide 5*-TTAGGG-3*) to the ends of
replicating chromosomes. Activation of telomerase has
been detected in a vast majority of human cancer cells.
Although recent studies have demonstrated the wide
occurrence of telomerase activation and Bcl-2 deregula-
tion in human cancer cells, it remains unclear whether
there is any linkage between the deregulation of Bcl-2
and telomerase activity in cancer cells. In the studies
presented here, we report that the stable overexpres-
sion of Bcl-2 in human cancer cells with low Bcl-2 ex-
pression was accompanied by increased levels of telom-
erase activity. In addition, using an IL-2-dependent
cytotoxic T-cell line, CTLL-2, we demonstrated that IL-2
deprivation (8 h), which is known to down-regulate Bcl-2
expression, also resulted in concurrent inhibition of te-
lomerase activity in the absence of any detectable apo-
ptosis and accumulation of cells in the G0/G1 phase of
the cell cycle. Re-exposure of IL-2-deprived CTLL-2 cells
to the recombinant IL-2 led to the up-regulation of both
Bcl-2 expression and telomerase activity. Taken to-
gether, these findings establish a close linkage between
the modulation of telomerase activity by survival factor
Bcl-2, and provide a model to study regulation of telom-
erase activity by an anti-apoptotic pathway that is
widely deregulated in cancer cells.
In recent years, it has become accepted that apoptosis or
programmed cell death plays an important role in the regula-
tion of tissue development and homeostasis (1, 2). Deregulation
of apoptosis has been shown to contribute to the pathogenesis
of a number of human diseases including cancer (3, 4). Regu-
lation of apoptosis is a complex process, which involves a num-
ber of cellular genes including that for B cell leukemia/lym-
phoma 2 (Bcl-2)1 and related family members (5). The bcl-2
gene was first identified at the breakpoint of a chromosomal
translocation t(14:18) in B follicular lymphoma (1). A bcl-2 gene
encodes a protein of 26 kDa that protects cells against apopto-
sis in a variety of experimental systems. Overexpression of
Bcl-2 has been shown to suppress the initiation of apoptosis in
response to a number of stimuli including anticancer drugs (1,
3, 5–9). Recent studies have indicated that cells from a variety
of human cancer may have a decreased ability to undergo
apoptosis in response to some physiologic stimuli (4), and a
defect in apoptosis may be involved in the aberrant survival
and/or development of cancer.
In addition to deregulation of apoptosis, it is increasingly
clear that the process of neoplasia is characterized by the
activation of telomerase, a ribonucleoprotein enzyme complex
that adds telomeric repeats (hexanucleotide 59-TTAGGG-39) to
the ends of replicating chromosomes, telomeres (10, 11). Te-
lomeres play an important role in chromosome structural in-
tegrity and functions including protection against the activa-
tion of DNA-damage checkpoints, and to counter the loss of
terminal DNA segments that occurs when linear DNA is rep-
licated (12). Recent reports have shown the involvement of
telomerase function in acquisition of immortality in cancer
cells as telomerase activity has been detected in the vast ma-
jority of human cancer cell lines and tumors tested, but is
either absent or expressed at very low levels in most (but not
all) somatic cells (13–15). The mechanism of telomerase acti-
vation during immortalization is not known at the moment. It
has been proposed (16) that telomerase activity is repressed in
somatic cells; during cell division, telomeres continue to
shorten until they reach a critical point at which some cellular
factor(s) detect the shortened telomere, resulting in the exit
from the cell cycle (M1 crisis) and the cell’s senescence. Muta-
tions in genes detecting genetic damage allow a clonal popula-
tion to continue to divide and escape senescence, resulting in
further telomeric loss. Further cell division leads to M2 crisis,
and most cells die. However, a rare cell somehow activates its
telomerase activity, resulting in stabilization of telomere
length and immortalization, which may represent an essential
requirement for the expansion of human cancer cells. Thus,
activation of telomerase during immortalization may be also
linked with the proliferation of cancer cells (16, 17).
Although both activation of telomerase activity and Bcl-2
deregulation have been widely detected in human tumor cells,
it remains unclear whether there is any linkage between the
deregulation of Bcl-2 and telomerase activity in cancer cells. In
the studies presented here, we investigated the influence of
Bcl-2 expression on the levels of telomerase activity. We report
that the overexpression of Bcl-2 in human cancer cells with low
levels of Bcl-2 such as cervical carcinoma HeLa cells and colo-
rectal carcinoma DiFi cells was accompanied by enhanced lev-
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els of telomerase activity compared with the levels of a telom-
erase activity present in control cells. In contrast, down-
regulation of Bcl-2 expression in an IL-2-dependent cytotoxic
T-cell line, CTLL-2, by IL-2 deprivation (8 h) resulted in con-
current inhibition of telomerase activity, and both of these
phenotypes (down-regulation of Bcl-2 and telomerase activity
in IL-2-deprived CTLL-2 cells) could be effectively reversed by
the addition of rIL-2. Taken together, these results demon-
strate a close linkage between the deregulation of survival
factor Bcl-2 and the telomerase activity in human cancer cells.
MATERIALS AND METHODS
Cell Lines—The cell lines used were human cervical carcinoma HeLa
cells (8), human colorectal carcinoma DiFi cells (9, 19), and mouse
cytotoxic T-cell line CTLL-2 (20). HeLa cells were cultured in modified
Eagle’s medium. DiFi cells were maintained in Dulbecco’s modified
Eagle’s medium/F-12 (1:1), and CTLL-2 cells were cultured in RPMI
1640 supplemented with 0.5 ng/ml rIL-2 (Immunex). All complete cul-
ture medium contained 10% fetal bovine serum.
Stable Expression of Bcl-2—Cells at a density of 106 cells/100-mm
diameter plate were transfected with plasmid DNA containing the
full-length human Bcl-2 cDNA and a selectable marker, a neomycin
phosphotransferase gene (21), by calcium phosphate precipitation pro-
cedures as described (6–9). Expression of Bcl-2 in individually isolated
clones was determined by immunoblotting with Bcl-2 mAb. Once a
stable cell line from each clone had been established, the drug was
removed from the culture medium. The clonal lines have been main-
tained in drug-free medium since then, and expression of Bcl-2 was
periodically examined. As a control, cells were transfected either with
an unrelated PKR-plasmid DNA containing neomycin marker or with
plasmid DNA containing neomycin phosphotransferase gene.
Cell Extracts and Immunoblotting—All experiments were performed
with cells in a logarithmic phase by controlling the plating density. Cell
extracts were prepared as described (26). Cell lysate containing equal
amounts of total protein (15–25 mg) were resolved on a 10% SDS-
polyacrylamide gel electrophoresis, followed by probing with an anti-
Bcl-2 mAb (Neomarkers Inc.) using alkaline phosphatase-conjugated
second antibody (7, 8). As an internal control, the same blot was cut into
two pieces, and the upper portion was probed with an unrelated heat
shock protein (Hsp)-70 mAb (Neomarkers Inc.) or actin antibody (Sig-
ma). Low molecular mass colored markers (Amersham Corp.) were used
as molecular weight standards. Quantitation of specific protein bands
was performed by using a protein data base scanner (Molecular
Dynamics).
Telomerase Assay—Subconfluent cultures were used to prepare the
detergent CHAPS extracts (13). Telomerase enzyme activity was meas-
ured by using a PCR-based telomeric repeat amplification protocol
(TRAP) kit from the Oncor Inc. as described (22, 23). Each reaction
product was amplified in the presence of an internal TRAP assay
standard (36 bp). The TRAP reaction products were separated by 10%
polyacrylamide gel electrophoresis, dried, and autoradiographed. The
basal level of telomerase activity (ladder formation) was measured by
serial dilution of the protein extracts, and an appropriate range of
protein concentration was selected that produced a linear response.
Each set of TRAP assay included control reaction tubes without any
extract, and with extracts treated with RNase A (200 mg/ml). To quan-
titate the levels of telomerase activity, the average densitometric opti-
cal density of first six TRAP bands after a primer band was presented
as a ratio to the internal TRAP assay standard band.
hTR Expression by PCR—Total RNA was prepared from subconflu-
ent cells by TRIzol reagent (Life Technologies, Inc.), and 1 mg of RNA
was subjected to RT-PCR using a RNA PCR core kit (Perkin Elmer) as
per manufacturer’s instruction (24). Amplification was carried out for
30 cycles. Equal aliquots of reaction product were analyzed by 2%
agarose gels containing ethidium bromide. Primers for hTR were syn-
thesized using the TRC3 sequence (24, 25). As PCR reaction product
size markers, we used glyceraldehyde-3-phosphate dehydrogenase
primers (reaction product about 300 bp), b2-microglobulin primers (re-
action product about 550 bp), and hTR product (about 150 bp) from
SW-480 positive control cells.
Cell Cycle Analysis—Cell cycle distribution was determined by stain-
ing with propidium iodide (Sigma) as described (26). Briefly, cells were
stained with propidium iodide and passed through the beam of an argon
ion laser turned to 514 (FAC/Scan; Becton Dickinson). The resulting
fluorescent signal was amplified, recorded in the memory, and analyzed
in the form of a DNA histogram, by using a computer program inter-
faced with the integrator.
RESULTS
To examine a possible relationship between Bcl-2 expression
and telomerase activity, we investigated whether deregulation
of Bcl-2 in HeLa cells would modulate the levels of telomerase
activity. For these studies, HeLa cells were transfected with a
Bcl-2 expression vector (21) and G418-resistant clonal cell lines
stably expressing Bcl-2 were generated (8). Fig. 1A shows the
levels of Bcl-2 protein in three out of seven such clones, HeLa/
Bcl-2.2 (lane 2), HeLa/Bcl-2.1 (lane 3), and HeLa/Bcl-2.3 (lane
4). Clones 1 and 3 express 4–6-fold higher levels of Bcl-2,
compared with the levels detected in the parental HeLa cells
(lane 1) or in the clone expressing an unrelated PKR/neo gene
(lane 5). Results in panel B show the effect of Bcl-2 overexpres-
sion on the levels of telomerase activity. It was noted that
overexpression of Bcl-2 in HeLa cells leads to a significant
enhancement (5–10-fold) in the levels of telomerase activity.
The observed increase in telomerase activity resulted from
overexpression of Bcl-2, since it was detected in both clone 1
and clone 3 (Fig. 1B) but not in control HeLa cells or HeLa cells
overexpressing an unrelated PKR/neo gene (HeLa/PKR.w1
cells). The observed increase in the levels of telomerase activity
in Bcl-2-overexpressing cells was not due to elongation of te-
lomere terminal restriction fragments (TRFs) as determined by
the Southern hybridization of HinfI-digested DNAs with telo-
FIG. 1. Overexpression of Bcl-2 en-
hances telomerase activity in HeLa
cells. A, levels of Bcl-2 in HeLa clones.
Lane 1, control HeLa; lane 2, clone 2; lane
3, clone 1; lane 4, clone 3; lane 5, HeLa/
PKR.W1 cells. As an internal control, the
upper portion of the Bcl-2 blot was re-
probed with an unrelated HSP-70 mAb.
B, CHAPS extracts were analyzed for te-
lomerase activity by TRAP assay as de-
scribed under “Materials and Methods.”
For each sample, 0.01 and 0.1 mg of pro-
tein was used. Lane 1, reaction without
any extract. The observed telomerase ac-
tivity was RNase A-sensitive, as it could
be inactivated completely by the pretreat-
ment of extracts with RNase A (200 mg/
ml). Results shown are representative of
four experiments.
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meric probe (data not shown). Lack of association between
telomerase activity and TRF length has been shown previously
(27, 28).
To determine whether the observed relationship between
Bcl-2 deregulation and enhanced telomerase activity is a phe-
nomena restricted to HeLa cells or whether they can show it
with other cells with low levels of Bcl-2, we examined the
influence of Bcl-2 deregulation on the levels of telomerase
activity in human colorectal carcinoma DiFi cells. Fig. 2 shows
the levels of Bcl-2 expression in DiFi cells, its five Bcl-2-over-
expressing clones, and three control neo transfectants. Overall,
there was a 6–10-fold overexpression of Bcl-2 in different clone
with highest being in clone 4 compared with parental DiFi cells
or control vector transfectants. Results in Fig. 2B illustrate
that all the Bcl-2-overexpressing clones have significantly ele-
vated levels (8–12-fold) of telomerase activity compared with
either control DiFi cells or neo clones. The observed differences
in the levels of telomerase activity were not due to the presence
of a potential telomerase inhibitor in extracts as we obtained
similar results when assayed the levels of telomerase activity
in Bcl-2-overexpressing DiFi clones as a function of protein
concentration (Fig. 3). The observed increase in the levels of
telomerase activity in DiFi/Bcl-2.5 cells compared with the
levels in control cells was not due to enhanced expression of
hTR component as determined by a quantitative RT-PCR assay
(Fig. 2C).
We next determined the effect of bi-directional regulation of
Bcl-2 expression on the status of telomerase activity in IL-2-
dependent CTLL-2 cells (29). As expected from the data in
literature (29), IL-2 deprivation of CTLL-2 cells for as little as
8 h resulted in the down-regulation (40% inhibition compared
with control cells) of Bcl-2 expression compared with the levels
present in control cells (Fig. 4B, compare lane 2 with lane 1),
and this was associated with down-regulation of telomerase
activity starting at 8 h post-IL-2 deprivation (Fig. 4A). The
observed early down-regulation in the levels of telomerase ac-
tivity was not due to IL-2 deprivation-associated G0/G1 cell
cycle arrest and/or apoptosis, as these phenotypic changes be-
came evident only at 24 h and not 8 h post-IL-2 deprivation
(Fig. 4C). This view was further supported by the data in Fig.
5A, demonstrating that there was no significant effect of 8 h of
IL-2 deprivation on the expression of apoptotic targets such as
PARP and lamin B. Since IL-2 is a known inducer of Bcl-2 (29),
we examined whether exposure of IL-2-deprived CTLL-2 cells
to rIL-2 will up-regulate telomerase activity. Results in Fig. 5
show that the down-regulation of both Bcl-2 expression and
telomerase activity could be reversed by the addition of rIL-2 to
IL-2-deprived (24 h) CTLL-2 cells. Other experiments indicated
that apoptosis triggered by IL-2 deprivation (24 h) was revers-
ible by the addition of IL-2, as expected from the published data
(29). Taken together, these results suggested that IL-2 regula-
tion of Bcl-2 expression may be closely related with modulation
of telomerase activity in CTLL-2 model system.
DISCUSSION
It is now well accepted that apoptosis is a physiological
phenomenon that plays an important role in the maintenance
of tissue homeostasis. Apoptosis is regulated by specific cellular
pathways including Bcl-2, deregulation of apoptosis contrib-
FIG. 3. Telomerase activity in DiFi and its Bcl-2-overexpress-
ing clones as a function of protein extracts. CHAPS extracts from
DiFi cells and its clones were analyzed for telomerase activity by TRAP
assay. For DiFi cells (lanes 1–3), TRAP assays were performed using
0.001, 0.01 and 0.1 mg of protein; for its Bcl-2 clones (lanes 4–15), TRAP
assays were performed using 0.0001, 0.001, and 0.01 mg of protein. Lane
16, cell extract (0.1 mg) from Bcl-2-overexpressing clone 4 was inacti-
vated by pretreatment with RNase A (200 mg/ml). Results shown are
representative of two experiments.
FIG. 2. Effect of Bcl-2 deregulation
on telomerase activity and hTR ex-
pression in DiFi cells. A, cells lysate (20
mg) from control DiFi cells (lane 1), 5 in-
dependent Bcl-2-overexpressing clones
(lanes 2–6), and three control neo clones
(lanes 7–9) were immunoblotted with an
anti-Bcl-2 mAb. As an internal control,
the upper portion of the blot was reprobed
with a HSP-70 mAb. B, CHAPS extracts
from DiFi cells and its clones were ana-
lyzed for telomerase activity by TRAP as-
say using 0.01 mg of protein. Lane 1, cell
extract (0.01 mg) from Bcl-2-overexpress-
ing clone 4 was pretreated with RNase A
(200 mg/ml). Lane 11, reaction without
cell extract. C, hTR expression. Total
RNAs (1 mg) from DiFi/Neo#2 cells (lane
1) and DiFi/Bcl-2.5 cells (lane 2) were sub-
jected to RT-PCR as described under “Ma-
terials and Methods.” Lane 3, 1 mg of RNA
from DiFi/Neo#2 cells without reverse-
transcriptase enzyme; lane 4, glyceralde-
hyde-3-phosphate dehydrogenase prod-
uct; lane 5, positive control hTR product;
lane 6, b2-microglobulin product.
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utes to the pathogenesis of a number of human diseases includ-
ing cancer, and Bcl-2 deregulation is frequently associated with
human cancer. Emerging lines of evidence suggest that in
addition to deregulation of apoptosis, the process of neoplasia
may be also driven by the activation of telomerase, a ribonu-
cleoprotein enzyme complex that adds telomeric repeats to the
ends of replicating chromosomes. Although activation of telom-
erase activity has been detected in human cancer cells, it re-
mains unclear whether there is any linkage between the de-
regulation of Bcl-2 and telomerase activity. The present study
was undertaken to investigate the possible relationship be-
tween the modulation of Bcl-2 expression and telomerase
activity.
We have now demonstrated that the deregulation of Bcl-2
expression in human cancer cells with low levels of Bcl-2 is
closely linked with the increased levels of telomerase activity
as overexpression of Bcl-2 in HeLa and DiFi cells was accom-
panied by increased telomerase activity compared with control
transfectants and/or parental cells. Since the activation of te-
lomerase activity has been shown to be associated with the
development of human cancer (16, 17), our finding of potential
involvement of survival factor Bcl-2 in the deregulation of
telomerase activity may provide an important insight into the
molecular mechanism involved in the initiation of cellular ma-
lignancies. The finding that Bcl-2 enhances telomerase activity
without elongation of telomeric TRFs in HeLa cells is interest-
ing, as it raises the possibility that additional pathway(s) such
as Bcl-2 deregulation that may influence telomerase activity in
cancer cells. The observation that HeLa clones with variable
levels of Bcl-2 expression (Fig. 1A) exhibited comparable en-
hanced levels of telomerase activity would suggest that the
deregulation of Bcl-2 over the presumptive threshold levels
may not further up-regulate telomerase activity, and this
threshold level could differ from one cell type to another. Our
finding that IL-2 deprivation of CTLL-2 cells for 8 h was suf-
ficient to down-regulate both Bcl-2 expression and telomerase
activity (Fig. 4) without any detectable apoptosis (Fig. 4C) is
important, as it suggests a close relationship between the levels
of survival factor Bcl-2 and telomerase activity in cancer cells.
Since IL-2 signal was sufficient to concurrently influence the
levels of both Bcl-2 and telomerase activity in CTLL-2 cells, it
remains to be resolved whether the observed modulation of
telomerase activity by IL-2 is mediated via changes in Bcl-2
expression and/or a direct effect of IL-2 and/or both Bcl-2 ex-
pression and telomerase activity are regulated via a IL-2-re-
sponsive common pathway(s). Taken together, these findings
provide new evidence in support of possible association be-
tween the deregulation of Bcl-2 and telomerase activity, and
are consistent with the predicted role of telomerase in main-
taining the integrity of chromosomes against DNA damage. It
remains to be seen whether the observed increase in the levels
of telomerase activity is a phenomenon restricted to Bcl-2 or a
general event associated with other anti-apoptotic gene prod-
ucts such as Bcl-XL.
Recent studies have indicated that the cells from a variety of
human cancer may have a decreased ability to undergo apo-
FIG. 4. IL-2 deprivation leads to in-
hibition of both Bcl-2 expression and
telomerase activity. IL-2-dependent
CTLL-2 cells were cultured in IL-2-de-
prived medium for 8, 24, and 48 h.
CHAPS extracts were assayed for telom-
erase activity (panel A) and Bcl-2 expres-
sion (panel B). Black wedges, 0.002, 0.01,
and 0.1 mg of protein. Lane 1, reaction
without cell extract. Results shown are
representative of four experiments. C,
FACS profile of CTLL-2 cells cultured in
the absence of IL-2 (2IL-2) for 0, 8, and
24 h. Cell cycle distribution at 0-h point,
35.3% G0/G1, 37% S, and 27.8% G2/M; 8-h
point, 24.6% G0/G1, 24% S, and 41.5%
G2/M; and 24-h point, 62.41% G0/G1,
16.6% S, and 21% G2/M. Bar at 24-h point
shows apoptotic cells.
FIG. 5. Regulation of telomerase activity by IL-2 in CTLL-2
cells. A, CTLL-2 cells were cultured in IL-2-deprived medium for 8 h
(lane 2) or 24 h (lane 3). At 24 h post-IL-2 deprivation, CTLL-2 culture
was supplemented by recombinant IL-2 (0.5 ng/ml) for 24 h (lane 4) or
48 h (lane 5). CHAPS extracts were analyzed for the expression of Bcl-2,
PARP, and lamin B by immunoblotting. B, CHAPS extracts from the
above samples were assayed for the levels of telomerase activity. Black
wedges, 0.01 and 0.1 mg of protein. Lane 11, reaction without cell
extract. Results shown are representative of three experiments.
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ptosis in response to physiologic stimuli, and a defect in apo-
ptosis has been proposed to be involved in the aberrant survival
and/or development of cancer (4). Therefore, in recent years,
approaches such as identification of agent(s) that can modulate
Bcl-2 have become the subject of active investigation to control
cancer cell growth. In addition to apoptosis, telomerase has
also attracted a great deal of interest as a possible target in
cancer biology. The apparent lower levels of measurable telom-
erase activity in many normal cells and its widespread detec-
tion in human cancer cells have raised the possibility that
telomerase may also serve an important target to control cell
growth. In spite of wide occurrence of deregulation of Bcl-2 and
telomerase activity in cancer cells, to date, to the best of our
knowledge, no close linkage between these two phenotypes has
been reported. Our findings of the modulation of telomerase
activity by a widely deregulated survival factor, Bcl-2, may
serve an important model to study the regulation of telomerase
activity by an apoptotic pathway and could open new possibil-
ities to develop novel strategies to control cancer cell growth by
co-targeting both pathways.
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